Genmab Adr stock is traded at $52.74, with a volume of 4,400,181. It is down -4.32% in the last 24 hours and up +39.52% over the past month. Genmab is a Copenhagen-based biotechnology company specializing in antibody therapeutics for the treatment of cancer. Genmab's proprietary antibody technologies are DuoBody, HexaBody, DuoHexaBody, and HexElect. Johnson & Johnson partnered with Genmab to create Darzalex, which is regarded as the standard of care for multiple myeloma and is Genmab's leading product. Genmab also has Tepezza for thyroid eye disease (partnered with Horizon), Kesimpta for relapsing multiple sclerosis (partnered with Novartis), Rybrevant (partnered with Johnson & Johnson) for non-small cell lung cancer (NSCLC), Tivdak (partnered with Seagen) for cervical cancer, and Epkinly (partnered with AbbVie) for diffuse large B-cell lymphoma. Genmab has several pipeline candidates targeting other oncologic indications.
Previous Close:
$55.12
Open:
$55.07
24h Volume:
4,400,181
Relative Volume:
0.51
Market Cap:
$32.43B
Revenue:
$3.91B
Net Income/Loss:
$823.88M
P/E Ratio:
39.77
EPS:
$1.33
Net Cash Flow:
$875.28M
1W Performance:
-7.57%
1M Performance:
+39.52%
6M Performance:
+89.10%
1Y Performance:
+82.87%
1-Day Range:
$0.00$0.00
1-Week Range:
$52.62$56.84
52-Week Range:
$23.62$59.97
Genmab Adr Stock (GMAB) Company Profile
Market Cap
Revenue
Net Income
Cash Flow
EPS